Loxo Oncol Eli Lilly Drug Patent Portfolio
Loxo Oncol Eli Lilly owns 1 orange book drug protected by 5 US patents Given below is the list of Loxo Oncol Eli Lilly's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10584124 | Crystalline forms | 10 Oct, 2038 | Active |
| US10786489 | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile | 10 Oct, 2038 | Active |
| US10112942 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | 10 Oct, 2037 | Active |
| US10137124 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | 10 Oct, 2037 | Active |
| US10172851 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | 10 Oct, 2037 | Active |
Latest Legal Activities on Loxo Oncol Eli Lilly's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Loxo Oncol Eli Lilly.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 21 Feb, 2024 | US10786489 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Aug, 2023 | US10584124 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Jun, 2022 | US10172851 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Apr, 2022 | US10137124 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Mar, 2022 | US10112942 |
| Post Issue Communication - Certificate of Correction | 25 Nov, 2020 | US10786489 |
| Sequence Moved to Public Database | 29 Sep, 2020 | US10786489 |
|
Recordation of Patent Grant Mailed
Critical
| 29 Sep, 2020 | US10786489 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 29 Sep, 2020 | US10786489 |
|
Email Notification
Critical
| 15 Sep, 2020 | US10786489 |
|
Issue Notification Mailed
Critical
| 09 Sep, 2020 | US10786489 |
| Dispatch to FDC | 21 Aug, 2020 | US10786489 |
|
Application Is Considered Ready for Issue
Critical
| 21 Aug, 2020 | US10786489 |
|
Issue Fee Payment Verified
Critical
| 20 Aug, 2020 | US10786489 |
|
Issue Fee Payment Received
Critical
| 20 Aug, 2020 | US10786489 |
Loxo Oncol Eli Lilly's Family Patents
Loxo Oncol Eli Lilly Drug List
Given below is the complete list of Loxo Oncol Eli Lilly's drugs and the patents protecting them.
1. Retevmo
Retevmo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10584124 | Crystalline forms |
10 Oct, 2038
(13 years from now)
| Active |
| US10786489 | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile |
10 Oct, 2038
(13 years from now)
| Active |
| US10112942 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
10 Oct, 2037
(12 years from now)
| Active |
| US10137124 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
10 Oct, 2037
(12 years from now)
| Active |
| US10172851 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
10 Oct, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Retevmo's drug page